Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Danaher is set to launch its first AI-powered autonomous research lab in early 2027, combining AI, robotics, and molecular tools to supercharge drug discovery. The lab promises to find new molecules eight times faster and generate ten times more target-binding molecules annually — freeing scientists to tackle the big-picture challenges that only humans can solve.
Danaher's AI-powered lab aims to turbocharge drug discovery by 2027
Life sciences giant Danaher is gearing up to launch its first fully autonomous, AI-powered research lab in early 2027. The lab will integrate AI, robotics, and technologies from multiple Danaher subsidiaries into a single connected workflow, focused on developing custom antibodies and other molecular tools critical to drug discovery.
The system works by using AI to design molecules that bind to specific biological targets, then autonomously builds and tests each candidate — feeding every result back into the model to continuously improve future designs. The goal is to let scientists step back from repetitive lab work and focus on the complex, high-judgment challenges where human insight is irreplaceable.
By the Numbers
Why it matters: Accelerating drug discovery could meaningfully shorten the timeline from scientific idea to viable therapy — a win for patients, researchers, and the broader healthcare system alike.
